Financials data is unavailable for this security.
View more
Year on year Bioventix PLC had net income fall -3.29% from 8.37m to 8.10m despite a 6.17% increase in revenues from 12.82m to 13.61m. An increase in the cost of goods sold as a percentage of sales from 6.46% to 6.80% was a component in the falling net income despite rising revenues.
| Gross margin | 93.20% |
|---|---|
| Net profit margin | 59.51% |
| Operating margin | 76.44% |
| Return on assets | 59.95% |
|---|---|
| Return on equity | 67.29% |
| Return on investment | 67.24% |
More ▼
Cash flow in GBPView more
In 2024, Bioventix PLC did not generate a significant amount of cash. However, the company earned 8.34m from its operations for a Cash Flow Margin of 61.32%. In addition the company generated 186.06k cash from investing, though they paid out 8.25m more in financing than they received.
| Cash flow per share | 1.55 |
|---|---|
| Price/Cash flow per share | 23.84 |
| Book value per share | 2.30 |
|---|---|
| Tangible book value per share | 2.30 |
More ▼
Balance sheet in GBPView more
| Current ratio | 7.42 |
|---|---|
| Quick ratio | 7.07 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in GBP
Year on year, growth in dividends per share increased 1.97% while earnings per share excluding extraordinary items fell by -3.43%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
| Div yield(5 year avg) | 3.37% |
|---|---|
| Div growth rate (5 year) | 16.25% |
| Payout ratio (TTM) | 99.92% |
| EPS growth(5 years) | 6.40 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -3.37 |
More ▼
